MCID: BRN028
MIFTS: 67

Brain Cancer

Categories: Rare diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Brain Cancer

MalaCards integrated aliases for Brain Cancer:

Name: Brain Cancer 12 52 14
Adult Brain Tumor 12 52 69
Primary Malignant Neoplasm of Brain 12 69
Neoplasm of Brain 12 29
Brain Neoplasms 42 69
Brain Tumors 52 41
Neoplasm of Unspecified Nature of Brain 12
Malignant Primary Brain Neoplasm 12
Adult Malignant Brain Neoplasm 12
Malignant Tumor of Adult Brain 12
Malignant Primary Brain Tumors 52
Malignant Primary Brain Tumor 12
Malignant Neoplasm of Brain 69
Malignant Tumor of Brain 12
Malignant Brain Tumour 12
Primary Brain Neoplasm 12
Brain Neoplasm, Adult 12
Brain Tumor, Primary 69
Primary Brain Tumor 12
Brain Tumor Primary 52
Tumor of the Brain 12
Brain Tumor, Adult 50
Bt - Brain Tumour 12
Brain Neoplasm 12

Classifications:



Summaries for Brain Cancer

MedlinePlus : 41 a brain tumor is a growth of abnormal cells in the tissues of the brain. brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. some are primary brain tumors, which start in the brain. others are metastatic, and they start somewhere else in the body and move to the brain. brain tumors can cause many symptoms. some of the most common are headaches, often in the morning nausea and vomiting changes in your ability to talk, hear, or see problems with balance or walking problems with thinking or memory feeling weak or sleepy changes in your mood or behavior seizures doctors diagnose brain tumors by doing a neurologic exam and tests including an mri, ct scan, and biopsy. treatment options include watchful waiting, surgery, radiation therapy, chemotherapy, and targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. many people get a combination of treatments. nih: national cancer institute

MalaCards based summary : Brain Cancer, also known as adult brain tumor, is related to brain glioma and anaplastic oligodendroglioma, and has symptoms including back pain, headache and pain. An important gene associated with Brain Cancer is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Pathways in cancer and MicroRNAs in cancer. The drugs Gliadel Wafer and Temodar have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and lung, and related phenotypes are Increased shRNA abundance (Z-score > 2) and homeostasis/metabolism

Disease Ontology : 12 A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain.

Wikipedia : 72 A brain tumor occurs when abnormal cells form within the brain. There are two main types of tumors:... more...

Related Diseases for Brain Cancer

Diseases related to Brain Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 235)
id Related Disease Score Top Affiliating Genes
1 brain glioma 30.8 ENO2 GFAP NES SYP TP53
2 anaplastic oligodendroglioma 30.2 GFAP PTEN SYP
3 brain tumor, childhood 12.0
4 epidermoid brain tumor 12.0
5 prostate cancer/brain cancer susceptibility, somatic 11.8
6 childhood germ cell brain tumor 11.7
7 brain stem cancer 11.3
8 optic disk drusen 11.1 IDH1 IDH2
9 early myoclonic encephalopathy 11.0 IDH1 IDH2 PTEN
10 nemaline myopathy 11.0 IDH1 IDH2
11 endolymphatic sac tumor 11.0 IDH1 IDH2
12 escobar syndrome, type b 11.0 ABCG2 BMI1
13 anca-associated vasculitis 10.9 IDH1 IDH2 MGMT
14 bannayan-riley-ruvalcaba syndrome 10.9 EGFR PTEN
15 mixed oligodendroglioma-astrocytoma 10.9 IDH1 IDH2 TP53
16 pediatric infratentorial ependymoma 10.9 EGFR TP53
17 congenital disorder of glycosylation, type if 10.9 IDH1 IDH2 TP53
18 posterior urethra cancer 10.9 ENO2 SMARCB1
19 pulmonary subvalvular stenosis 10.9 AKT1 EGFR PTEN
20 ovarian mucinous cystadenofibroma 10.9 GFAP IDH2 PTEN
21 peritoneal serous adenocarcinoma 10.8 IDH1 IDH2 TP53
22 nodular medulloblastoma 10.8 ENO2 GFAP SMARCB1
23 glucocorticoid-induced osteoporosis 10.8 ALK TP53
24 gorham's disease 10.8 ALK EGFR ENO2
25 rectum kaposi's sarcoma 10.8 EGFR PTEN TP53
26 myxedema 10.8 EGFR PTEN TP53
27 meningitis and encephalitis 10.8 ENO2 GFAP
28 pancoast tumor 10.8 GFAP TP53
29 sparse hair ptosis mental retardation 10.8 ABCB1 EGFR TP53
30 integumentary system cancer 10.8 AKT1 EGFR TP53
31 omphalomesenteric cyst 10.8 GFAP IDH2 MGMT
32 cleft lip palate dysmorphism kumar type 10.8 EGFR PTEN TP53
33 pilocytic astrocytoma of cerebellum 10.8 IDH1 TP53
34 brain stem astrocytic neoplasm 10.8 GFAP TP53
35 pancreatic somatostatinoma 10.8 AKT1 EGFR TP53
36 gestational choriocarcinoma 10.8 AKT1 ENO2 TP53
37 rectum squamous cell carcinoma 10.8 AKT1 MGMT TP53
38 tendon sheath lipoma 10.8 GFAP IDH2 TP53
39 endometriosis of uterus 10.8 EGFR PTEN TP53
40 paranasal sinus cancer 10.8 ENO2 SYP
41 ampulla of vater small cell carcinoma 10.8 ENO2 SYP
42 iodine hypothyroidism 10.8 GFAP IDH1 TP53
43 brenner tumor of the vagina 10.8 ALK PTEN TP53
44 apocrine adenocarcinoma 10.7 EGFR IDH1 IDH2 TP53
45 prostate cancer, hereditary, x-linked 1 10.7 AKT1 PTEN TP53
46 brenner tumor of ovary 10.7 ALK PTEN TP53
47 estrogen-receptor negative breast cancer 10.7 AKT1 EGFR TP53
48 nasopharyngeal carcinoma 10.7 EGFR IDH1 PTEN TP53
49 trachea squamous cell carcinoma 10.7 AKT1 EGFR PTEN TP53
50 extragonadal nonseminomatous germ cell tumor 10.7 ALK EGFR TP53

Comorbidity relations with Brain Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Brain Edema
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation Hypertension, Essential
Obstructive Hydrocephalus Schizophreniform Disorder

Graphical network of the top 20 diseases related to Brain Cancer:



Diseases related to Brain Cancer

Symptoms & Phenotypes for Brain Cancer

UMLS symptoms related to Brain Cancer:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Brain Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.85 NES
2 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.85 NES
3 Increased shRNA abundance (Z-score > 2) GR00366-A-147 9.85 NES
4 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.85 PTEN
5 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.85 PTEN
6 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.85 IDH2 NES PTEN AKT1 BIRC6
7 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.85 PTEN
8 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.85 IDH2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.85 IDH2 AKT1 BIRC6
10 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.85 NES
11 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.85 NES
12 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.85 IDH2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-205 9.85 NES
14 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.85 PTEN
15 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.85 BIRC6
16 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.85 IDH2 PTEN AKT1 BIRC6
17 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.85 AKT1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.85 PTEN
19 Increased shRNA abundance (Z-score > 2) GR00366-A-69 9.85 IDH2
20 Increased shRNA abundance (Z-score > 2) GR00366-A-70 9.85 AKT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.85 IDH2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.85 BIRC6
23 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.85 AKT1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.85 AKT1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.85 PTEN

MGI Mouse Phenotypes related to Brain Cancer:

44 (show all 20)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 GFAP IDH1 MGMT MYCN PTCH1 PTEN
2 cellular MP:0005384 10.35 ABCG2 AKT1 BIRC6 DMBT1 EGFR ENO2
3 growth/size/body region MP:0005378 10.35 GFAP IDH1 MYCN PTCH1 PTEN SMARCB1
4 behavior/neurological MP:0005386 10.33 PTEN SMARCB1 SYP TP53 ABCB1 AKT1
5 cardiovascular system MP:0005385 10.32 ABCB1 AKT1 BIRC6 EGFR GFAP IDH2
6 mortality/aging MP:0010768 10.3 ABCB1 AKT1 ALK BIRC6 DMBT1 EGFR
7 immune system MP:0005387 10.27 ABCB1 ABCG2 AKT1 BIRC6 DMBT1 EGFR
8 hematopoietic system MP:0005397 10.26 ABCG2 AKT1 BIRC6 EGFR IDH1 MYCN
9 digestive/alimentary MP:0005381 10.22 SMARCB1 TP53 ABCB1 DMBT1 EGFR GFAP
10 embryo MP:0005380 10.21 AKT1 BIRC6 DMBT1 EGFR MYCN PTCH1
11 nervous system MP:0003631 10.21 ALK BIRC6 EGFR ENO2 GFAP MYCN
12 endocrine/exocrine gland MP:0005379 10.2 ABCB1 AKT1 ALK BIRC6 EGFR MGMT
13 liver/biliary system MP:0005370 10.13 ABCB1 ABCG2 AKT1 BIRC6 EGFR MYCN
14 neoplasm MP:0002006 10.1 AKT1 ALK DMBT1 EGFR IDH2 MGMT
15 muscle MP:0005369 10.03 AKT1 EGFR GFAP MYCN PTCH1 PTEN
16 normal MP:0002873 10.02 ABCG2 AKT1 BIRC6 EGFR GFAP MYCN
17 reproductive system MP:0005389 9.81 AKT1 ALK EGFR MYCN PTCH1 PTEN
18 pigmentation MP:0001186 9.65 PTEN TP53 ALK EGFR PTCH1
19 respiratory system MP:0005388 9.65 AKT1 ALK EGFR ENO2 IDH1 MGMT
20 vision/eye MP:0005391 9.23 ALK EGFR GFAP MYCN PTCH1 PTEN

Drugs & Therapeutics for Brain Cancer

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Gliadel Wafer 17 46 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997
2
Temodar 17 46 TEMOZOLOMIDE Schering-Plough August 1999
3
Alecensa 17 ALECTINIB HYDROCHLORIDE Roche December 2015

Drugs for Brain Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 749)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 2216-51-5 16666
2
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754 657311
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
4
Mannitol Approved, Investigational Phase 4,Phase 1,Phase 2 69-65-8 453 6251
5
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 1 28523-86-6 5206
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 437-38-7 3345
7
Dacarbazine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 4342-03-4 5351166
8
Temozolomide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 85622-93-1 5394
9
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3 76631-46-4, 113775-47-6 68602 5311068 56032
10
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
11
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 2078-54-8 4943
12
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
13
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
14 Piracetam Approved Phase 4,Phase 2 7491-74-9
15
Clevidipine Approved Phase 4 167221-71-8
16
Hydralazine Approved Phase 4 86-54-4 3637
17
Labetalol Approved Phase 4 36894-69-6 3869
18
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
19
Methylphenidate Approved, Investigational Phase 4,Phase 3 113-45-1 4158
20
Thrombin Approved Phase 4
21
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 1 2180-92-9, 38396-39-3 2474
22
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
23
Levobupivacaine Approved Phase 4 27262-47-1 92253
24
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
25
Cabergoline Approved Phase 4,Phase 3,Phase 2 81409-90-7 54746
26
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
27
Somatostatin Approved Phase 4,Phase 2,Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
28
Remifentanil Approved Phase 4,Phase 3 132875-61-7 60815
29
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
30
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
31
Ibuprofen Approved Phase 4,Phase 3 15687-27-1 3672
32
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2 57-27-2 5288826
33
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
34
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
35
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
36
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 120014-06-4 3152
37
Lamotrigine Approved, Investigational Phase 4,Phase 1,Phase 2 84057-84-1 3878
38
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 19982-08-2 4054
39
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2 148553-50-8 5486971
40
Topiramate Approved Phase 4,Phase 1,Phase 2 97240-79-4 5284627
41
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99-66-1 3121
42
Benzocaine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 1994-09-7, 94-09-7 2337
43
Ephedrine Approved Phase 4 299-42-3 9294
44
Oxymetazoline Approved Phase 4 1491-59-4 4636
45
Phenylephrine Approved Phase 4 59-42-7 6041
46
Pseudoephedrine Approved Phase 4 90-82-4 7028
47
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
48
Cefazolin Approved Phase 4 25953-19-9 656510 33255
49
Cefdinir Approved Phase 4 91832-40-5 6915944
50
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529

Interventional clinical trials:

(show top 50) (show all 2325)

id Name Status NCT ID Phase Drugs
1 Characterization of Receptors in Non-functioning Pituitary Macroadenomas Unknown status NCT00852501 Phase 4
2 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
3 Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases Unknown status NCT01926171 Phase 4 Icotinib plus WBRT
4 Comparison of 20% Mannitol and 3% Hypertonic Saline for Cerebral Relaxation During Elective Supratentorial Craniotomies Unknown status NCT01745081 Phase 4 20% mannitol bolus administration;Hypertonic saline 3% bolus administration
5 Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery Completed NCT00571155 Phase 4 levetiracetam
6 Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Completed NCT02034708 Phase 4 Dotarem®;Gadovist®/Gadavist®
7 Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
8 Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors Completed NCT00075166 Phase 4
9 A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients Completed NCT00952081 Phase 4 Clevidipine
10 Multihance at 3 Tesla in Brain Tumors Completed NCT00395863 Phase 4 Multihance;Arm 2 - Magnevist
11 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
12 Phase IV Bioseal Study in Brain Tumor Surgery Completed NCT02034799 Phase 4
13 Scalp Nerve Block and Opioid Consumption in Brain Surgery Completed NCT02057367 Phase 4 Scalp block with 0.5% plain Marcaine;Scalp block with 0.9% normal saline
14 Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants Completed NCT02708056 Phase 4 Sugammadex
15 The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block Completed NCT02558569 Phase 4 Levobupivacaine
16 Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
17 Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy Completed NCT02810899 Phase 4 dexmedetomidine;normal saline
18 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
19 Crossover Comparison of MultiHance and Dotarem Completed NCT02070380 Phase 4 MultiHance 0.1 mmol/kg;Dotarem;MultiHance 0.05 mmol/kg
20 Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain Completed NCT01613417 Phase 4 gadoteridol;gadobutrol
21 A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain Completed NCT00323102 Phase 4 Multihance
22 Validation of 3 Dimensional Laparoscopic System in Disral Pancreatectomy and Splenectomy Completed NCT02757690 Phase 4
23 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
24 Remifentanil Infusion Alone During the Closure Period for Early Emergence Following Craniotomy Completed NCT02593942 Phase 4 Remifentanil;Propofol
25 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
26 Effect of 5 Years of GH Replacement on Atherosclerosis Completed NCT00462475 Phase 4 Recombinant Growth Hormone, Genotropin (Pfizer)
27 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
28 Sleep Quality After Stellate-ganglion Block of Patients Undergoing Breast Cancer Operation Completed NCT02651519 Phase 4 0.25% ropivacaine hydrochloride;saline
29 Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy Recruiting NCT02193568 Phase 4
30 Vasopressor Effects in Anesthetized Patients Recruiting NCT02713087 Phase 4 Ephedrine;Phenylephrine
31 Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery Recruiting NCT02964416 Phase 4 Injection Tramadol
32 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Recruiting NCT02478346 Phase 4 Fluorescein Sodium
33 Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Recruiting NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
34 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
35 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Recruiting NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
36 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
37 Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer Recruiting NCT03016741 Phase 4 Prednisone;Abiraterone Acetate;Enzalutamide
38 Quality Improvement and Practice Based Research in Neurology Using the EMR Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
39 Comparison of Efficacy and Safety of the Postoperative Analgesia Methods Not yet recruiting NCT02929147 Phase 4 Morphine;Dexketoprofen;Placebo
40 Treatment of Resectable Malignant Brain Tumors Terminated NCT00415467 Phase 4
41 Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients Terminated NCT00727090 Phase 4 Conivaptan
42 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
43 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Terminated NCT02028325 Phase 4 Fluorescein Sodium
44 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
45 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
46 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
47 Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children Unknown status NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;etoposide;trofosfamide/etoposide
48 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
49 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
50 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride

Search NIH Clinical Center for Brain Cancer

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: brain neoplasms

Genetic Tests for Brain Cancer

Genetic tests related to Brain Cancer:

id Genetic test Affiliating Genes
1 Neoplasm of Brain 29

Anatomical Context for Brain Cancer

MalaCards organs/tissues related to Brain Cancer:

39
Brain, Breast, Lung, Pituitary, Bone, Testes, T Cells

Publications for Brain Cancer

Articles related to Brain Cancer:

(show top 50) (show all 508)
id Title Authors Year
1
The biochemical, nanomechanical and chemometric signatures of brain cancer. ( 28688336 )
2018
2
Fusion of gelonin and anti-insulin-like growth factor-1 receptor (IGF-1R) affibody for enhanced brain cancer therapy. ( 28900896 )
2017
3
Corrigendum to "Inferring the 1985-2014 impact of mobile phone use on selected brain cancer subtypes using Bayesian structural time series and synthetic controls" [Environ. Int. (2016), 97, 100-107]. ( 28131518 )
2017
4
Targeted Drug Delivery via Folate Receptors for the Treatment of Brain Cancer: Can the Promise Deliver? ( 28842300 )
2017
5
Toxicity of Cisplatin-Loaded Poly Butyl Cyanoacrylate Nanoparticles in a Brain Cancer Cell Line: Anionic Polymerization Results ( 28440967 )
2017
6
A mathematical theory of shape and neuro-fuzzy methodology-based diagnostic analysis: a comparative study on early detection and treatment planning of brain cancer. ( 28321787 )
2017
7
Brain cancer therapy. ( 28104878 )
2017
8
Detecting and treating brain cancer. ( 28611178 )
2017
9
Radiochemical Evaluation and <i>In Vitro</i> Assessment of the Targeting Ability of a Novel <sup>99m</sup>Tc-HYNIC-RGD for U87MG Human Brain Cancer Cells. ( 28681701 )
2017
10
Characterization of PTEN mutations in brain cancer reveals that pten mono-ubiquitination promotes protein stability and nuclear localization. ( 28263967 )
2017
11
Rethinking Brain Cancer Therapy: Tumor Enzyme Activatable Theranostic Nanoparticles. ( 28929923 )
2017
12
Investigation of Vitamin D Receptor Gene Polymorphism in Pediatric Patients with Brain Cancer. ( 28900319 )
2017
13
Residential radon exposure and brain cancer: an ecological study in a radon prone area (Galicia, Spain). ( 28620182 )
2017
14
Towards carborane-functionalised structures for the treatment of brain cancer. ( 28886331 )
2017
15
Nasal HPpSIS administration enhances NGF and tumor suppressor protein, p73 in human brain cancer tissues: preliminary data. ( 28239803 )
2017
16
Brain cancer: Temozolomide improves outcomes. ( 28857072 )
2017
17
Robust and fast characterization of OCT-based optical attenuation using a novel frequency-domain algorithm for brain cancer detection. ( 28327613 )
2017
18
Role of key genetic mutations on increasing migration of brain cancer cells through confinement. ( 28620782 )
2017
19
Using Epigenetic Reprogramming to Treat Pediatric Brain Cancer. ( 28486100 )
2017
20
TPGS-chitosan cross-linked targeted nanoparticles for effective brain cancer therapy. ( 28254282 )
2017
21
Metabolomic signature of brain cancer. ( 28618012 )
2017
22
Utility of neurological smears for intrasurgical brain cancer diagnostics and tumour cell percentage by DESI-MS. ( 28112301 )
2017
23
The small-molecule kinase inhibitor D11 counteracts 17-AAG-mediated up-regulation of HSP70 in brain cancer cells. ( 28542269 )
2017
24
Combined Proteomic-Molecular Epidemiology Approach to Identify Precision Targets in Brain Cancer. ( 28657708 )
2017
25
Fitness, body composition and vascular health in adolescent and young adult survivors of paediatric brain cancer and cranial radiotherapy. ( 28930627 )
2017
26
Non-invasive Photodynamic Therapy in Brain Cancer by Use of Tb(3+)-Doped LaF3 Nanoparticles in Combination with Photosensitizer Through X-ray Irradiation: A Proof-of-Concept Study. ( 28110445 )
2017
27
Largest brain cancer study offers clues to inherited risk. ( 28722792 )
2017
28
Time-A and oxygen-dependent expression and regulation of NDRG1 in human brain cancer cells. ( 28498432 )
2017
29
Risk of severe acute liver injury among patients with brain cancer treated with temozolomide: a nested case-control study using the healthcore integrated research database. ( 28717885 )
2017
30
Radiomic Phenotyping in Brain Cancer to Unravel Hidden Information in Medical Images. ( 28079714 )
2017
31
Brain Cancer Stem Cells in Adults and Children: Cell Biology and Therapeutic Implications. ( 28374184 )
2017
32
Evaluation of [(18)F]-ATRi as PET tracer for in vivo imaging of ATR in mouse models of brain cancer. ( 28157626 )
2017
33
QuickStats: Brain Cancer Death Rates Among Children and Teens Aged 1-19 Years,* by Sex(a8 ) and Age Group - United States, 2013-2015. ( 28472022 )
2017
34
British-led research uncovers new details on brain cancer. ( 28421936 )
2017
35
Genetically engineered rat gliomas: PDGF-driven tumor initiation and progression in tv-a transgenic rats recreate key features of human brain cancer. ( 28358926 )
2017
36
Towards Targeting PI3K-Dependent Regulation of Gene Expression in Brain Cancer. ( 28556811 )
2017
37
Enhancement of apoptotic activities on brain cancer cells via the combination of I^-tocotrienol and jerantinine A. ( 28545672 )
2017
38
Trends in brain cancer mortality among U.S. Gulf War veterans: 21 year follow-up. ( 28780478 )
2017
39
The roles of microglia/macrophages in tumor progression of brain cancer and metastatic disease. ( 28410147 )
2017
40
Ethanol-based proliposome delivery systems of paclitaxel for in vitro application against brain cancer cells. ( 27834116 )
2016
41
Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by Mn(III) n-butoxyethylpyridylporphyrin-based redox modifier. ( 27224425 )
2016
42
Pre-Adult MRI of Brain Cancer and Neurological Injury: Multivariate Analyses. ( 27446888 )
2016
43
217a88YAP Is Ready to Rac and Rho: Elucidation of a Novel YAP-Driven Network That Potentiates Brain Cancer Cell Dispersal and Confers Poor Survival in Patients. ( 27399496 )
2016
44
Immunotherapy of Brain Cancer. ( 27260656 )
2016
45
Engineering a Brain Cancer Chip for High-throughput Drug Screening. ( 27151082 )
2016
46
Neural networks improve brain cancer detection with Raman spectroscopy in the presence of operating room light artifacts. ( 27604560 )
2016
47
Automatic quality control in clinical (1) H MRSI of brain cancer. ( 27071355 )
2016
48
Raman spectroscopy detects distant invasive brain cancer cells centimeters beyond MRI capability in humans. ( 28018730 )
2016
49
Correction: Exploring the Support Needs of Family Caregivers of Patients with Brain Cancer Using the CSNAT: A Comparative Study with Other Cancer Groups. ( 26799832 )
2016
50
Lomustine Nanoparticles Enable Both Bone Marrow Sparing and High Brain Drug Levels - A Strategy for Brain Cancer Treatments. ( 26903051 )
2016

Variations for Brain Cancer

ClinVar genetic disease variations for Brain Cancer:

6 (show top 50) (show all 65)
id Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.388C> T (p.Arg130Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121909224 GRCh37 Chromosome 10, 89692904: 89692904
2 PTEN NM_000314.6(PTEN): c.1003C> T (p.Arg335Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121909231 GRCh37 Chromosome 10, 89720852: 89720852
3 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
4 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
5 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
6 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
7 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
8 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
9 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
10 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
11 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
12 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
13 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
14 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
15 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
16 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
17 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
18 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
19 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
20 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
21 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic/Likely pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
22 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
23 ALK NM_004304.4(ALK): c.3824G> A (p.Arg1275Gln) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs113994087 GRCh37 Chromosome 2, 29432664: 29432664
24 ALK NM_004304.4(ALK): c.3383G> C (p.Gly1128Ala) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs113994088 GRCh37 Chromosome 2, 29445450: 29445450
25 ALK NM_004304.4(ALK): c.3575G> C (p.Arg1192Pro) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs113994089 GRCh37 Chromosome 2, 29443642: 29443642
26 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
27 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
28 BRAF NM_004333.4(BRAF): c.1780G> A (p.Asp594Asn) single nucleotide variant Pathogenic/Likely pathogenic rs397516896 GRCh37 Chromosome 7, 140453155: 140453155
29 PIK3CA NM_006218.3(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic/Likely pathogenic rs397517201 GRCh37 Chromosome 3, 178936095: 178936095
30 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
31 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic/Likely pathogenic rs148924904 GRCh37 Chromosome 17, 7578442: 7578442
32 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
33 TP53 NM_000546.5(TP53): c.580C> T (p.Leu194Phe) single nucleotide variant Pathogenic/Likely pathogenic rs587780071 GRCh37 Chromosome 17, 7578269: 7578269
34 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
35 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
36 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587781288 GRCh38 Chromosome 17, 7675190: 7675190
37 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
38 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587782289 GRCh37 Chromosome 17, 7577575: 7577575
39 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
40 PIK3CA NM_006218.3(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 GRCh38 Chromosome 3, 179199690: 179199690
41 PIK3CA NM_006218.3(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 GRCh37 Chromosome 3, 178952074: 178952074
42 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
43 PTEN NM_000314.6(PTEN): c.517C> T (p.Arg173Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913293 GRCh37 Chromosome 10, 89711899: 89711899
44 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796
45 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic/Likely pathogenic rs760043106 GRCh38 Chromosome 17, 7674947: 7674947
46 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
47 TP53 NM_000546.5(TP53): c.833C> T (p.Pro278Leu) single nucleotide variant Pathogenic/Likely pathogenic rs876659802 GRCh37 Chromosome 17, 7577105: 7577105
48 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
49 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
50 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh38 Chromosome 1, 114713907: 114713907

Cosmic variations for Brain Cancer:

9 (show all 29)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10704 TP53 central nervous system,brain,primitive neuroectodermal tumour-medulloblastoma,classic c.844C>T p.R282W 28
2 COSM10738 TP53 central nervous system,brain,primitive neuroectodermal tumour-medulloblastoma,classic c.542G>A p.R181H 28
3 COSM10659 TP53 central nervous system,brain,primitive neuroectodermal tumour-medulloblastoma,classic c.817C>T p.R273C 28
4 COSM11517